Strides Pharma Science is confident in reaching its $250 million target for its US business, according to Arun Kumar, Executive Chairperson & MD, in an interview with CNBC-TV18 on Wednesday. “We are on track to meet our $250 million top-end guidance for our US business, and we have strong confidence in its continued growth,” Kumar stated.
Speaking about the firm’s third-quarter results and the performance of its US operations, Kumar noted, “Q3 historically proves to be a robust quarter for our US operations due to seasonality, particularly with flu and cold products, which form a significant portion of our portfolio. It’s typical for Q3 to be a peak quarter for us in the US.” Kumar highlighted the significance of the recent approval for Suprep, stating, “Suprep’s approval is significant, and along with a series of recent approvals, we’ve seen an increase in our product portfolio. Suprep will play a substantial role in this strategy. We anticipate launching the product in the next few weeks, and we expect to see its full impact in the next financial year.”
Discussing Stride Pharma’s growth strategy, Kumar mentioned, “We are confident in guiding the US market for 15% growth from here, as we have consistently done in our calls. Despite outpacing our peer group significantly in the US market, both domestically and internationally, we believe this growth target is reasonable.”
Headquartered in Bengaluru, Strides Pharma Science Ltd is an Indian pharmaceutical company with a market capitalization of ₹6,280 crore. The company specializes in manufacturing pharmaceutical products, over-the-counter drugs, and nutraceuticals. With a focus on sustainable margins and market share, Strides Pharma Science is positioned for continued success in the pharmaceutical industry.